Evidence map›Paper›PMID 39824175›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

First-in-human trial of atrial fibrillation ablation using real-time tissue optical assessment to predict pulsed field lesion durability.

Raphael P Martins, Giorgi Papiashvili, Askar Sabirov, Sherzod Sabirov, David Herranz, Christophe Bailleul, Atul Verma

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06700226 (AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06700226 nacompletednot on this map

AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man

TypeinterventionalSponsorMedlumicsRan2024 to 2025Enrolled10ConditionsParoxysmal AFArmsAblaView® Unipolar PFA System
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Latest Advances and Ongoing Challenges in Pulsed Field Ablation.Arrhythmia & electrophysiology review · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raphael P MartinsCardiology Department CHU Rennes, Univ Rennes, CIC 1414, INSERM, LTSI-UMR 1099, F-35000 Rennes, France.ORCID 0000-0001-5716-6712
Giorgi PapiashviliCardiology Department, Israeli-Georgian Medical Research Clinic Healthycore, Tbilisi, Georgia.ORCID 0000-0002-6183-6683
Askar SabirovCardiology Department, AKFA Medline University Hospital, Tashkent, Uzbekistan.
Sherzod SabirovCardiology Department, Ezgu Niyat Medical Center, Tashkent, Uzbekistan.ORCID 0000-0003-4177-7740
David HerranzClinical Department, MedLumics, Tres Cantos, Madrid, Spain.
Christophe BailleulClinical Department, MedLumics, Tres Cantos, Madrid, Spain.ORCID 0000-0003-3821-1754
Atul VermaDivision of Cardiology, McGill University Medical Center, D13.173, 1650 Cedar Avenue, Montreal H3B 1A4, Quebec, Canada.ORCID 0000-0002-1020-9727

Funding

MedLumics S.L
6 · The paper itself

Abstract

aimsLoss of bipolar electrograms immediately after pulsed field ablation (PFA) makes lesion durability assessment challenging.

objectiveThe aim of this trial (NCT06700226) was to evaluate a novel ablation system that can optically predict lesion durability by detecting structural changes in the tissue during ablation. METHODS AND

resultsPatients with paroxysmal atrial fibrillation underwent pulmonary vein isolation (PVI) using PFA (AblaView®, MedLumics). Using polarization-sensitive optical coherence reflectometry (PS-OCR), reflective characteristics of myocardial tissue and visualization of real-time contrast between healthy tissue and ablated tissue using a drop in tissue birefringence (BiR) was assessed. Wide antral PVI was performed using single point irrigated PFA (unipolar, 1800V, 3 trains, 21 s). Remapping was performed at 3 months. Primary efficacy outcome was the ability of PS-OCR to predict lesion durability at 3-month remapping. Serious adverse events were recorded. Ten patients were included. In total, 38/40 PVs could be isolated with the system. The mean drop of BiR was 17.3 ± 11.5%. Dragging across the ablation lines showed a persistent drop in BiR. During the remap procedures (8/10 patients ablated only with PFA), 12 PVs (37.5%) were found to be electrically reconnected. The mean loss of BiR during all PFA for durable lesions was 20.9%, while only 10.1% BiR loss was observed during the index ablation for reconnected areas (P < 0.001). None of the points with ≥17% loss of birefringence was found to be reconnected.

conclusionThis first-in-human study supports the use of real-time drop in tissue BiR for lesion assessment and durability during PFA delivery, and its procedural safety.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsTomography, Optical CoherenceAction PotentialsAgedBirefringenceElectrophysiologic Techniques, CardiacEquipment DesignFemaleHeart RateHumansMaleMiddle AgedPredictive Value of TestsTime FactorsAblationAtrial fibrillationBirefringencePolarization sensitive optical coherence reflectometryPulsed field ablation

Identifiers

PMID39824175
PMCPMC11832195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.